Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Immunotherapy in R/M HNSCC Progressed on Prior Immunotherapy
NCT04326257Phase 2Completed
- Start
- May 2020
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab, ipilimumab in squamous cell carcinoma of the head and neck (HNSCC). Started May 2020; status: completed.
02
Drugs
relatlimabipilimumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04326257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326257.